<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582216</url>
  </required_header>
  <id_info>
    <org_study_id>Kine-001</org_study_id>
    <nct_id>NCT02582216</nct_id>
  </id_info>
  <brief_title>3D Augmented Reality Mirror Visual Feedback Applied to the Treatment of Unilateral Upper Extremity Neuropathic Pain.</brief_title>
  <official_title>3D Augmented Reality Mirror Visual Feedback Therapy Applied to the Treatment of Persistent, Unilateral Upper Extremity Neuropathic Pain: A Preliminary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has two objectives. First, to introduce a new virtual reality method that&#xD;
      incorporates the mechanisms used in mirror visual feedback through a three-dimensional (3D)&#xD;
      augmented virtual reality system. Second, to evaluate the efficiency of this new method on a&#xD;
      convenience sample of patients presenting with unresolved neuropathic pain (CRPS, PLP,&#xD;
      plexopathy, stroke) who were not responding adequately to both pharmaceutical management and&#xD;
      traditional mirror therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient receives 5 treatment periods over a total period of 1 week, where each treatment&#xD;
      period lasts a total of 20 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain on the Visual Analog Scale (VAS)</measure>
    <time_frame>baseline and week</time_frame>
    <description>Visual Analogic Scale assessed pain intensity before and after the intervention. Possible scores range from 0 (no pain) to 10 (worst possible pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Assessed With DN4 Questionnaire</measure>
    <time_frame>1 week</time_frame>
    <description>DN4 (Douleur Neuropathique en 4 Questions) is a screening tool for neuropathic pain consisting of interview questions (DN4-interview) and physical tests.&#xD;
When the practitioner suspects neuropathic pain, the DN4 questionnaire is useful as a diagnostic tool.&#xD;
This questionnaire is divided into 4 questions representing 10 check items:&#xD;
The practitioner questions the patient himself and completes the questionnaire&#xD;
For each item, he must provide a &quot;yes&quot; or &quot;no&quot; answer&#xD;
At the end of the questionnaire, the practitioner counts the responses, 1 for each &quot;Yes&quot; and 0 for each &quot;no&quot;.&#xD;
The sum obtained gives the Patient Score, noted out of 10.&#xD;
If the patient's score is 4/10 or more, the test is positive (sensitivity at 82.9%; specificity at 89.9%)&#xD;
Dn4 questionnaire were completed before and 24 hour after the last session</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Questionnaire de Saint-Antoine</measure>
    <time_frame>1 week</time_frame>
    <description>French adaptation of Melzack's MC Gill Pain Questionnaire (MPQ). It is a questionnaire of 61 qualifying words divided into 17 subclasses: 9 sensory, 7 emotional, 1 evaluative. The patient is asked to select the adjectives and then rate them from 0 (not at all) to 4 (extremely). This self-assessment scale allows clinical practice to specify the participation of the sensory and the emotional in pain intensity.&#xD;
self-questionnaire scoring the sensory and emotional qualities of the pain</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Neuralgia</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3D augmented reality</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3D augmented reality</intervention_name>
    <description>Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neuropathic pain in the unilateral upper extremity scored by DN4 questionnaire&#xD;
&#xD;
          -  At least 3 months symptom duration following injury&#xD;
&#xD;
          -  Minimum pain of 40 on a visual analogue scale (VAS);&#xD;
&#xD;
          -  A drug treatment regimen that was stable for at least 2 weeks.&#xD;
&#xD;
          -  Subjects were allowed to participate if they presented with any of the following: (1)&#xD;
             A CRPS diagnosis, in accordance with the International Association for the Study of&#xD;
             Pain criteria, Phantom Limb Pain (PLP), or spinal cord injury or plexopathy; and (2)&#xD;
             an history of being treated before by conventional mirror therapy but, in their case,&#xD;
             the mirror therapy failed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral injury,&#xD;
&#xD;
          -  Patients with epilepsy&#xD;
&#xD;
          -  Side effects known to 3D (such as nausea, cephalalgia)&#xD;
&#xD;
          -  Cognitive disorder&#xD;
&#xD;
          -  Poor knowledge of the French language.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <results_first_submitted>June 16, 2016</results_first_submitted>
  <results_first_submitted_qc>August 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2020</results_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open Label</title>
          <description>3D augmented reality</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label</title>
          <description>3D augmented reality</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain on the Visual Analog Scale (VAS)</title>
        <description>Visual Analogic Scale assessed pain intensity before and after the intervention. Possible scores range from 0 (no pain) to 10 (worst possible pain)</description>
        <time_frame>baseline and week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>each patients received 5 3D augmented reality over a period of 5 days. Each treatment lasted a total of 20 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Pain on the Visual Analog Scale (VAS)</title>
          <description>Visual Analogic Scale assessed pain intensity before and after the intervention. Possible scores range from 0 (no pain) to 10 (worst possible pain)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>vas baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vas after 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropathic Pain Assessed With DN4 Questionnaire</title>
        <description>DN4 (Douleur Neuropathique en 4 Questions) is a screening tool for neuropathic pain consisting of interview questions (DN4-interview) and physical tests.&#xD;
When the practitioner suspects neuropathic pain, the DN4 questionnaire is useful as a diagnostic tool.&#xD;
This questionnaire is divided into 4 questions representing 10 check items:&#xD;
The practitioner questions the patient himself and completes the questionnaire&#xD;
For each item, he must provide a &quot;yes&quot; or &quot;no&quot; answer&#xD;
At the end of the questionnaire, the practitioner counts the responses, 1 for each &quot;Yes&quot; and 0 for each &quot;no&quot;.&#xD;
The sum obtained gives the Patient Score, noted out of 10.&#xD;
If the patient's score is 4/10 or more, the test is positive (sensitivity at 82.9%; specificity at 89.9%)&#xD;
Dn4 questionnaire were completed before and 24 hour after the last session</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>Each patient received a 3D augmented reality</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropathic Pain Assessed With DN4 Questionnaire</title>
          <description>DN4 (Douleur Neuropathique en 4 Questions) is a screening tool for neuropathic pain consisting of interview questions (DN4-interview) and physical tests.&#xD;
When the practitioner suspects neuropathic pain, the DN4 questionnaire is useful as a diagnostic tool.&#xD;
This questionnaire is divided into 4 questions representing 10 check items:&#xD;
The practitioner questions the patient himself and completes the questionnaire&#xD;
For each item, he must provide a &quot;yes&quot; or &quot;no&quot; answer&#xD;
At the end of the questionnaire, the practitioner counts the responses, 1 for each &quot;Yes&quot; and 0 for each &quot;no&quot;.&#xD;
The sum obtained gives the Patient Score, noted out of 10.&#xD;
If the patient's score is 4/10 or more, the test is positive (sensitivity at 82.9%; specificity at 89.9%)&#xD;
Dn4 questionnaire were completed before and 24 hour after the last session</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24H after the last treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Questionnaire de Saint-Antoine</title>
        <description>French adaptation of Melzack's MC Gill Pain Questionnaire (MPQ). It is a questionnaire of 61 qualifying words divided into 17 subclasses: 9 sensory, 7 emotional, 1 evaluative. The patient is asked to select the adjectives and then rate them from 0 (not at all) to 4 (extremely). This self-assessment scale allows clinical practice to specify the participation of the sensory and the emotional in pain intensity.&#xD;
self-questionnaire scoring the sensory and emotional qualities of the pain</description>
        <time_frame>1 week</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Virtual training activities were terminated if patients complained about the development of headache or nausea, which are the most common side effects provoked by the use of stereovision systems similar to the 3DARS system. These symptoms were not present in this population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Open Label</title>
          <description>patients received a 3D augmented reality treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dominique Mouraux</name_or_title>
      <organization>HÃ´pital Erasme</organization>
      <phone>+32/2.555.38.48</phone>
      <email>dmouraux@ulb.ac.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

